心泰醫療：2024中期報告.pdf

1、Interim Report2024中 期 報 告Stock Code 股份代號:2291*For identification purposes only*僅供識別Definitions 2Corporate Information 6Financial Highlights 9Management Discussion and Analysis 11Other Information 38Review Report 45Consolidated Balance Sheet 46Consolidated Income Statement 50Consolidated Statement of

2、 Cash Flows 53Consolidated Statement of 55 Changes in Owners EquityNotes to the 2024 Interim 57 Financial Statements釋義 2公司資料 6財務摘要 9管理層討論與分析 11其他資料 38審閱報告 45合併資產負債表 46合併利潤表 50合併現金流量表 53合併所有者權益變動表 55二零二四年半年度財務報表附註 57Contents 目錄Definitions釋義Interim Report 2024二零二四中報2LEPU ScienTech Medical Technology(S

3、hanghai)Co.,Ltd.樂普心泰醫療科技（上海）股份有限公司於本報告中，除非文義另有所指，下列詞彙具有下文所載涵義：In this report,the following expressions have the meanings set out below unless the context requires otherwise:“Actual Controller”the individual or entity that can control a company by way of investment relationship,contracts or other arr

4、angements according to the Listing Rules of the ChiNext Board of the Shenzhen Stock Exchange(深圳證券交易所創業板股票上市規則)where Lepu Medical,our controlling shareholder,is listed實際控制人指根據控股股東樂普醫療上市地的 深圳證券交易所創業板股票上市規則，通過投資關係、協議或者其他安排能夠實際支配公司行為的個人或實體“ASD”atrial septal defect,a remnant opening,or a defect,between t

5、he left and right atria resulting from the abnormal development,absorption and fusion of the atrial septum during embryonic development房間隔缺損指房間隔缺損，胚胎發育過程中，房間隔的發育、吸收和融合出現異常，導致左、右心房之間的殘留未閉或缺損“Audit Committee”the audit committee of the Board審計委員會指董事會審計委員會“Board”the board of Directors of the Company董事會指

6、本公司董事會“CG Code”the Corporate Governance Code as set out in Appendix C1 to the Listing Rules 企業管治守則 指上市規則 附錄C1所載 企業管治守則“CHD”congenital heart disease,the formation of the heart and blood vessels during embryonic development or abnormal development or failure to close the channels that should be automa